Authors
Loading...
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Our analyses could not fully ascribe the effects of semaglutide on cardiovascular disease to known risk factors with any certainty. Whether we combine all risk factors together or look at some subsets of the risk factors, no more than half of the reduction in heart disease could be explained by the changes in these risk factors. These results suggest that semaglutide should be considered as a cardiovascular disease reduction drug and not just as a weight loss drug.”
“By all accounts, the remarkable story of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in cardiovascular medicine has been one of serendipity. Two years ago, in the European Heart Journal, we wrote that the journey of semaglutide was one such story—a drug born to lower glucose that has become the most versatile weapon against cardiometabolic-, kidney-, and obesity-related disease”
Narrative review reveals unresolved central and peripheral mechanisms of semaglutide in metabolic disease, highlighting key targets for next-generation drug design.
Verma et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: